- Home
- RDZN vs CVRX Comparison
RDZN vs CVRX Comparison
Compare RDZN & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDZN | CVRX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | 308 | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 139.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDZN | CVRX |
|---|---|---|
| Price | $1.40 | $5.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | ★ 791.1K | 308.1K |
| Earning Date | 02-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | $33.77 | $17.17 |
| Revenue Next Year | $51.46 | $17.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $0.81 | $4.37 |
| 52 Week High | $2.56 | $11.30 |
Technical Indicators
Market Signals| Indicator | RDZN | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 49.78 |
| Support Level | $1.22 | $5.06 |
| Resistance Level | $1.49 | $5.95 |
| Average True Range (ATR) | 0.14 | 0.40 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 11.31 | 57.48 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.